BPC
VKTX icon

Banque Pictet & Cie’s Viking Therapeutics VKTX Stock Holding History

Banque Pictet & Cie’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-48,492
Closed -$1.58M – 399
2026
Q1 		$1.58M Buy
48,492
+13,466
+38% +$433K 0.01% 242
2025
Q4 		$1.23M Buy
35,026
+25,849
+282% +$916K 0.01% 248
2025
Q3 		$241K Sell
9,177
-60
-0.6% -$1.79K ﹤0.01% 379
2025
Q2 		$245K Sell
9,237
-618
-6% -$16.3K ﹤0.01% 347
2025
Q1 		$238K Buy
+9,855
New +$311K ﹤0.01% 370

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Banque Pictet & Cie's VKTX Position: Q2 2026 in Review

Banque Pictet & Cie sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 48,492 shares — an estimated $1.58M sold.

Banque Pictet & Cie first reported a position in VKTX in Q1 2025 and held it in 5 quarters. The position peaked at $1.58M in Q1 2026. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Banque Pictet & Cie reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Banque Pictet & Cie sold 48,492 Viking Therapeutics shares in Q2 2026, an estimated $1.58M.
  • Banque Pictet & Cie first reported a position in Viking Therapeutics in Q1 2025 and held it in 5 quarters.
  • Banque Pictet & Cie's Viking Therapeutics position peaked at $1.58M in Q1 2026.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Banque Pictet & Cie's 13F filing for Q2 2026, filed 24 Jul 2026.